Opening New Possibilities in Intractable Disease Treatment
with 20 Years of Validated Innovation
An innovative solution that simultaneously regulates the Gut-Immune-Kidney (Tri-Axes) using Multi-Mechanism Therapeutics (MMT).
Opening New Possibilities in Intractable Disease Treatment
with 20 Years of Validated Innovation
An innovative solution that simultaneously regulates the Gut-Immune-Kidney (Tri-Axes) using Multi-Mechanism Therapeutics (MMT).
Current Challenges in Pet Treatment
Optimal pet health is maintained only when the Gut-Immune-Kidney (Tri-Axes) are closely interconnected to maintain the body's balance.
Accumulation of internal toxins
Imbalance in gut/immune system
Collapse of Tri-Axes interaction
Reduced treatment efficacy & complications
Intractable diseases
That's Why ANIBIOME
Developed MMT
Simultaneously regulates Gut-Immune-Kidney (Tri-Axes) to
address root causes and
maximize treatment efficacy
SCROLL DOWN
Multi-Mechanism Therapeutics (MMT) simultaneously regulates the core Gut-Immune-Kidney Axes (Tri-Axes), thereby targeting root causes and maximizing treatment outcomes
Building integrated technology synergy through
natural-based therapeutics, microbiome platform,
and clinical nutrition-based customized feed development
Safe, naturally-derived ingredients
minimizing side effects
while providing fundamental therapeutic benefits
Gut microbiome balance
for immune-metabolic regulation
and systemic health improvement
Scientifically-backed
customized nutrition solutions
for optimal therapeutic outcomes
Human Clinical Efficacy Validation ① Nicotine Toxin Removal in Smokers
In a clinical study of 10 healthy adult, nicotine was removed by up to 69% after 2 hours, and oxidative stress decreased by 33% after 4 hours.
Human Clinical Efficacy Validation ② Dioxin Reduction in Incinerator Workers
In a clinical trial with 3 incinerator workers, an average 39% reduction (PCDD+PCDF) was achieved after 4 weeks. This is a groundbreaking result considering dioxin's half-life of 7-10 years.
* Lead Research Institution: Y University School of Medicine Leading Research Center (Period: December 1, 2006 - February 28, 2007)
Current Challenges in Pet Treatment
Optimal pet health is maintained only when the Gut-Immune-Kidney (Tri-Axes) are closely interconnected to maintain the body's balance.
Accumulation of internal toxins
Imbalance in gut/immune system
Collapse of Tri-Axes interaction
Reduced treatment efficacy & complications
Intractable diseases
Conventional Treatment vs MMT Treatment Comparison
Single-Target Approach
Targets specific symptoms
Multi-Mechanism Regulation
Integrated Tri-Axes approach
Symptom Relief Focus
Temporary improvement
Root Cause Resolution
Sustained health improvement
Limited
Single pathway only
Gut-Immune-Kidney Axes
Three axes simultaneous regulation
Potential Side Effects
Chemical-based
High Safety
Natural ingredient-based
Not Provided
No detoxification function
Detoxification
Nicotine 69%, Dioxin 39% ↓
Limited Long-term Data
Short-term studies
20 Years Validated
Human clinical-based (since 2006)
Temporary Improvement
High recurrence risk
Fundamental Health Improvement
Sustained effects
Traditional
Single Technology Focus
Three R&D Pillars Integration
Natural, Microbiome, Clinical Nutrition
That's Why ANIBIOME Developed MMT
An innovative solution that simultaneously regulates Gut-Immune-Kidney (Tri-Axes)
to address root causes and maximize treatment efficacy
SCROLL DOWN
Multi-Mechanism Therapeutics (MMT) simultaneously regulates the core Gut-Immune-Kidney Axes (Tri-Axes), thereby targeting root causes and maximizing treatment outcomes
Building integrated technology synergy through natural-based therapeutics, microbiome platform, and clinical nutrition-based customized feed development
Safe, naturally-derived ingredients
minimizing side effects
while providing fundamental therapeutic benefits
Gut microbiome balance
for immune-metabolic regulation
and systemic health improvement
Scientifically-backed
customized nutrition solutions
for optimal therapeutic outcomes
Human Clinical Efficacy Validation ① Nicotine Toxin Removal in Smokers
In a clinical study of 10 healthy adult, nicotine was removed by up to 69% after 2 hours, and oxidative stress decreased by 33% after 4 hours.
Human Clinical Efficacy Validation ② Dioxin Reduction in Incinerator Workers
In a clinical trial with 3 incinerator workers, an average 39% reduction (PCDD+PCDF) was achieved after 4 weeks. This is a groundbreaking result considering dioxin's half-life of 7-10 years.
* Lead Research Institution: Y University School of Medicine Leading Research Center (Period: December 1, 2006 - February 28, 2007)
Conventional Treatment vs MMT Treatment Comparison
| Comparison | Conventional Treatment | MMT Treatment |
|---|---|---|
| Treatment Approach | Single-Target Approach Targets specific symptoms only | Multi-Mechanism Simultaneous Regulation Integrated Tri-Axes approach |
| Treatment Goal | Symptom Relief Focus Temporary improvement | Root Cause Resolution Sustained health improvement |
| Scope of Action | Limited Single pathway only | Gut-Immune-Kidney Axes Three axes simultaneous regulation |
| Safety | Potential Side Effects Chemical-based | High Safety Natural ingredient-based |
| Toxin Removal | Not Provided No detoxification function | Detoxification Technology Nicotine 69%, Dioxin 39% ↓ |
| Clinical Validation | Limited Long-term Data Short-term efficacy/toxicity studies | 20 Years Validated Human clinical-based (since 2006) |
| Treatment Efficacy | Temporary Improvement High recurrence risk | Fundamental Health Improvement Sustained effects |
| R&D Capability | Traditional Single Technology Focus | Three R&D Pillars Integration Natural, Microbiome, Clinical Nutrition |
Company Name | ANIBIOME Co., Ltd.
CEO | Chang Un-sang
Tel | 070-7776-0029
Email | cus1619@gmail.com
Business Registration No. |
222-88-03513
Address
A-625, Gwangmyeong G-Tower,
190, Soha-ro, Gwangmyeong-si,
Gyeonggi-do, Republic of Korea
Company Name | ANIBIOME Co., Ltd.
CEO | Chang Un-sang Tel | 070-7776-0029 Email | cus1619@gmail.com Business Registration No. | 222-88-03513
Address | A-625, Gwangmyeong G-Tower, 190, Soha-ro, Gwangmyeong-si, Gyeonggi-do, Republic of Korea
©2021. Anibiome Co., Ltd. All Rights Reserved.
